Four companies (GSK, Pfizer, Sanofi, and MSD) together occupy over 80 percent of the global market for vaccines. Moreover, vaccines are an important part of these companies’ revenue streams, making up between 13 and 21 percent of total revenues in 2019.
Insights on Vaccines’ Importance to Global Revenues
We have more than 10 vaccines and medicines in the late-stage portfolio that could change medical practice and have sales potential in excess of one billion dollars – and several, such as our RSV vaccine in older adults, could have multibillion dollar potential
Hal Barron, chief scientific officer & president R&D, GSK (January 2021)
Prevnar 13 is Pfizer’s pneumococcal vaccine that protects against infections such as pneumonia and meningitis, as well as other infections caused by pneumococcus including ear and sinus. In 2014, the US Centers for Disease Control and Prevention (CDC) recommended the immunization for adults ages 65 and older in addition to young children, typically those under the age of 2, and adults with certain chronic conditions. And that sent the profits on Prevnar skyrocketing to USD 23.4 billion since just 2015
Brittany Shoot, Fortune (February 2019)
[Sanofi] enjoys a very, very broad portfolio and it’s also a leader in vaccine manufacturing … the whole move towards vaccination due to COVID has really grown quite a lot and Sanofi is going to benefit from that the next couple of years
Boris Schlossberg, managing director, BK Asset Management (December 2020)
We really wanted to have capacity to cover the global birth cohort [with Gardasil]. If you think about the number of births every year, they’re somewhere in the order of 125 million globally. If you assume basically an 80 percent vaccine coverage rate, you want around 200 million doses to protect that portion of the population. And that’s kind of the ballpark that we’ve been looking at
Mike Nally, chief medical officer, MSD (September 2020)
Add Your Comment
You must be logged in to post a comment.